![System.Func`1[System.String]](/siteassets/images/z-mckesson-logosicons/health-systems2.png)
Four Key Aspects of Generic Drugs
MHS In the News: Andrew Wilson Answers "One Burning Question"
A 340B expert discusses how to make sure the program is benefiting patients.
By
Date
August 17, 2021
Listen time: 7 minutes
A key goal of the 340B Drug Pricing Program is to allocate additional revenue to health services for patients in underserved communities, such as free care for uninsured patients, free vaccines, mental health treatment and more. While overall 340B savings is tracked and managed by hospitals, oftentimes it is not delivered back to the hospitals to invest in such programs. Instead, it can be consumed by high billing and operating costs.
In a conversation with Keith Streckenbach of Pharmacy Practice News, Andrew Wilson, vice president, 340B Solutions for McKesson, discusses this one burning question pertaining to 340B: “Have you examined how your actions with the 340B Drug Pricing Program are benefitting your patients?”
Listen to hear what he shared.
Related Stories
Top Prescribed Perspectives Reads for January
Top Reads of December
Meet Our Expert: How Rafael Saenz Designed a Path to His Dreams and (May Have) Engineered His Own Luck
Top Reads of November
Event Preview: An Exclusive Look at McKesson’s Industry Experts and Insights You’ll Find at the 2025 ASHP Midyear Meeting
6 Questions Health Systems Should Ask Their Partners – Beyond Price
Top Reads of October
A Look Back at American Pharmacists Month
Podcast: What Does a Successful Infusion Strategy Really Look Like for Health Systems?